Biodesix Inc
NASDAQ:BDSX

Watchlist Manager
Biodesix Inc Logo
Biodesix Inc
NASDAQ:BDSX
Watchlist
Price: 1.48 USD 1.37% Market Closed
Market Cap: 215.3m USD
Have any thoughts about
Biodesix Inc?
Write Note

Biodesix Inc
Non-Reccuring Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Biodesix Inc
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
Biodesix Inc
NASDAQ:BDSX
Non-Reccuring Items
-$44k
CAGR 3-Years
N/A
CAGR 5-Years
52%
CAGR 10-Years
N/A
Quest Diagnostics Inc
NYSE:DGX
Non-Reccuring Items
-$69m
CAGR 3-Years
N/A
CAGR 5-Years
9%
CAGR 10-Years
-13%
CVS Health Corp
NYSE:CVS
Non-Reccuring Items
-$1.7B
CAGR 3-Years
1%
CAGR 5-Years
8%
CAGR 10-Years
-12%
Cigna Corp
NYSE:CI
Non-Reccuring Items
-$2.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-74%
Laboratory Corporation of America Holdings
NYSE:LH
Non-Reccuring Items
-$389.2m
CAGR 3-Years
-58%
CAGR 5-Years
-22%
CAGR 10-Years
-35%
R1 RCM Inc
NASDAQ:RCM
Non-Reccuring Items
-$96.7m
CAGR 3-Years
N/A
CAGR 5-Years
-13%
CAGR 10-Years
-5%
No Stocks Found

Biodesix Inc
Glance View

Market Cap
215.3m USD
Industry
Health Care

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The company is headquartered in Boulder, Colorado and currently employs 218 full-time employees. The company went IPO on 2020-10-28. The firm uses its artificial intelligence (AI) platform, Diagnostic Cortex, to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus on lung disease. In addition to its diagnostic tests, it provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development and commercialization of companion diagnostics. The firm offers blood-based lung cancer tests across the lung cancer continuum of care, including Nodify XL2 and Nodify CDT tests, and GeneStrat and VeriStrat tests. The firm also offers three SARS-CoV-2 tests under the Biodesix WorkSafe testing program, such as Bio-Rad SARS-CoV-2 ddPCR test, Platelia SARS-CoV-2 Total Ab test and cPass SARS-CoV-2 Neutralization Antibody Test.

BDSX Intrinsic Value
1.96 USD
Undervaluation 24%
Intrinsic Value
Price

See Also

What is Biodesix Inc's Non-Reccuring Items?
Non-Reccuring Items
-44k USD

Based on the financial report for Dec 31, 2023, Biodesix Inc's Non-Reccuring Items amounts to -44k USD.

What is Biodesix Inc's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 5Y
52%

Over the last year, the Non-Reccuring Items growth was 99%.

Back to Top